COYA News & Events

Coya Therapeutics announces the publication of a research study led by Dr. David Beers and Dr. Stanley Appel at the Houston Methodist Neurological Institute. The study included the longitudinal measurement of well-characterized serum biomarkers of lipid peroxidation, systemic inflammation, and axonal injury, and the functional evaluation over time of 100 randomly selected patients with ALS. The study has been published in the peer-reviewed journal Annals of Clinical and Translational Neurology. "These findings demonstrate significant correlations between biomarkers of inflammation, oxidative stress, and axonal injury and survival in patients with ALS", said Dr. Fred Grossman, President and Chief Medical Officer of Coya. "In our ongoing ALSTARS trial, we are measuring NfL as a secondary endpoint, along with inflammation markers including 4-HNE and ox-LDL as exploratory endpoints. Together, these efforts will further inform the growing body of evidence supporting the role of inflammation in neurodegenerative diseases."

Coya Therapeutics announced that founder Howard Berman has stepped down as Executive Chairman and as a member of the Board, and that Mark Pavao has been appointed to the Board as an independent director. Berman became Executive Chairman in November 2024 as part of a planned CEO transition that established Arun Swaminathan, as the Company's CEO. Dr. Berman's departure from the Executive Chairman role was a contemplated next step in that process. Coya is also proud to announce that Mark H. Pavao is joining its Board, to fill the Board seat resulting from Dr. Berman's departure. Pavao has held senior leadership roles at Biotech Value Advisors, LLC, R-Pharm US and Bristol-Myers Squibb.

Coya Therapeutics announced the publication of a research study at the Houston Methodist Neurological Institute, demonstrating the involvement of the peripheral immune system in the neuroinflammatory profile of frontotemporal dementia, or FTD. The study has been published in the peer-reviewed journal Brain Communications and can be accessed here. Blood samples were obtained from 27 patients clinically diagnosed with FTD and 25 age-matched healthy individuals as a control group. Comprehensive analyses revealed significantly lower regulatory T cell immunomodulatory suppressive function in FTD patients compared to healthy controls. Transcriptomic profiling of monocytes showed different degrees of dysregulation of immune-related genes in samples from FTD patients. Consistent with the reduced anti-inflammatory function observed in Tregs, proteomic analysis of plasma inflammatory mediators showed a significant increase in the pro-inflammatory cytokine TNFalpha and the chemokines CXCL10, CCL3, CCL19, CSF1 and CXCL12 in FTD patients compared to healthy controls. The company believes the results of this study demonstrate that there is a dysregulation of inflammation-related gene expression in peripheral monocytes and an increase of plasma inflammatory chemokines and cytokines in FTD. In addition, the data provide evidence of compromised immunomodulatory function of Tregs. The company believes that biomarker data from this research study further support the previously reported findings of an academic clinical study of low-dose interleukin 2 and CTLA-4 Ig in patients with FTD. The subcutaneous administration of LD IL-2 and CTLA-4 Ig significantly increased the number and function of Tregs as early as 2 weeks after initiation of treatment and remained elevated throughout the study. Consistent with the improvement of Treg immunomodulatory function, study patients did not show clinical cognitive decline as measured by the validated tools MoCA and CDR-FTLD over the 22-week treatment period. Overall, treatment with LD IL-2 and CTLA-4 Ig was well tolerated. The most frequent adverse events were mild injection-site erythema.

Coya Therapeutics (COYA) announced that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2.522M shares of its common stock in a private placement at a price of $4.40 per share. The offering is expected to close on or about January 30, subject to the satisfaction of customary closing conditions. The investors in the offering are Dr. Reddy's (RDY), $10M, and Greenlight Capital, an existing institutional stockholder of the company. The gross proceeds to the Company from the private placement are expected to be approximately $11.1M, before deducting offering expenses payable by the company. No broker, placement agent or investment banker was engaged in the transaction. The company intends to use the net proceeds to accelerate tech transfer and scale-up manufacturing activities for low dose IL-2 to support the commercial readiness of COYA 302.